Introduction 15
Lysosomal storage diseases (LSDs) comprise a large group of genetic disorders caused by 16 deficiencies in lysosomal proteins; many lack effective treatments. Mucopolysaccharidosis type I 17 (MPSI) is a common LSD caused by insufficient iduronidase (IDUA) activity that results in 18 glycosaminoglycan (GAG) accumulation and progressive multi-systemic deterioration that 19 severely affects the neurological and musculoskeletal systems 1 . Current interventions for MPSI 20 include enzyme replacement therapy (ERT) and allogeneic hematopoietic stem cell transplantation 21 (allo-HSCT); both have limited efficacy. ERT does not cross the blood-brain barrier, requires 22 costly life-long infusions, and inhibitory antibodies can further decrease enzyme bioavailability 2 
. 23
Allo-HSCT results in better outcomes than ERT by providing a persistent source of enzyme and 24 tissue macrophages that can migrate into affected organs, including the brain, to deliver local 25 enzyme [3] [4] [5] . However, allo-HSCT has significant limitations, including the uncertain availability of 26 suitable donors, delay in treatment (allowing for irreversible progression), and transplant-27 associated morbidity and mortality such as graft-versus-host disease and drug-induced 28 immunosuppression. 29 though 1% of cells eventually became positive. Most cells with intermediate fluorescence 114
converted to YFP-high (80%) (Fig. 2b) . In these cultures with mixed YFP-positive and negative 115 6 cells, grown under expansion conditions, the fraction of YFP-positive cells remained stable for 30 116 days, suggesting that neither the modification, nor the overexpression of the enzyme, nor the 117 reporter impacted the cells' proliferative potential. 118
When compared to mock-treated cells expressing endogenous IDUA levels, YFP-high cells 119
secreted 250-fold and 25-fold more enzyme for the SFFV and PGK-driven cassettes respectively, 120 while cell lysates expressed 600 and 50-fold more enzymatic activity (Fig. 2c) . When YFP-high 121 IDUA-HSPCs were co-cultured with patient-derived MPSI fibroblasts, they led to a decrease in 122 the average area of lysosomal-associated membrane protein 1 (LAMP-1) positive specks, 123 consistent with reduced lysosomal compartment size and cross-correction of the cellular phenotype 124 ( Fig. 2d) . These data confirm that IDUA-HSPCs secrete supra-physiological IDUA levels and that 125 the secreted IDUA has the post-translational modifications required for uptake into MPSI cells, 126 thereby biochemically cross-correcting the patient derived enzyme deficient cells. 127
For IDUA-HSPCs to successfully correct biochemical abnormalities in the organs affected in 128 MPSI, they must differentiate into monocytes that will migrate to and differentiate into tissue-129 resident macrophages such as microglia (brain), Kupffer cells (liver), osteoclasts (bone), and 130 splenic macrophages to deliver the enzyme and cross-correct enzyme-deficient cells. To confirm 131 that IDUA-HSPC could generate macrophages and that these cells can continue to produce IDUA, 132 we differentiated these cells in culture and assayed for IDUA activity (Supplementary Data 2 133 and Fig. 2e ). These IDUA-HPSC-derived macrophages secreted 182-fold and 69-fold more IDUA 134 for the SFFV and PGK-driven cassettes respectively than mock-cell-derived macrophages. 135
Likewise, lysates exhibited 75-fold and 24-fold more IDUA activity (Fig. 2f) . These data 136 established that IDUA-HPSC can reconstitute monocyte/macrophages in vitro and that IDUA-137 HPSC-derived macrophages also exhibit enhanced IDUA expression. 138 139
Preserved repopulation and differentiation potential in IDUA-HSPCs 140
To determine if HSPCs that have undergone genome editing can engraft in vivo, we performed 141 serial engraftment studies into NOD-scid-gamma (NSG) mice. We first tested cells modified with 142 the SFFV and PGK constructs expressing YFP, which allowed us to identify the modified cells in 143 7 vivo. Equal numbers of CB and PB-derived mock, YFP-negative (YFP-), and YFP-positive 144 (YFP+) cells were transplanted intra-femorally into sub-lethally irradiated 6 to 8-week-old mice. 145
Primary human engraftment was measured 16 weeks-post-transplantation by establishing the 146 percent of bone marrow (BM) cells expressing both human CD45 and human leukocyte antigens 147 (HLA-ABC) out of total mouse and human CD45+ cells (Extended Data Figure 3b and Fig. 3a) . 148
For the PGK-driven constructs, the median frequencies of hCD45 + /HLA + cells in BM were as 149 follows: Mock 76.25% (min-max: 46.4-95.4%), YFP-21.5% (0.06-89.5%), YFP+ 4.3% (0.06-150 96%) (Fig. 3b) . This showed a 5-fold drop in repopulation capacity in cells that underwent HR-151 GE (YFP+) compared to cells that did not but were also exposed to RNP, AAV transduction, and 152 sorting (YFP-). The median frequency of human cells expressing YFP was 0.6% (0-18.5%) and 153 95.8% (1-100%) for YFP-and YFP+ transplants respectively, confirming that edited cells had 154 engrafted in these mice ( Fig. 3c) . Human cells were also found in the peripheral blood with 155 frequencies of 31/3.1/1.1% in mock, YFP-, and YFP+ cells respectively (Fig. 3b) . 156
The apparent engraftment advantage of cells that had not undergone HR-GE was also examined 157 by transplanting bulk populations of HSPCs modified with the cassette without YFP. In two 158 independent experiments, an initial fraction of targeted alleles of 28% (43% modified cells) 159 declined to 5.2% and 6.5% in the engrafted cells (8 and 10% modified cells) despite big differences 160 in human chimerism (Fig. 3c, d) . This corresponded to a 5-fold drop in donor 1 and 4-fold drop in 161 donor 2. Interestingly, this fall in targeted alleles showed significant variation in individual mice 162 (2 to 10-fold). This data re-demonstrated the observed loss in engraftment potency after 163 modification and supports the idea that the HR-GE cell population has fewer clones with long-164 term repopulation potential. 165
Serial transplantation is considered a gold standard to assess self-renewal capacity of HSCs. For 166 secondary transplants, we isolated human CD34 + cells from the bone marrow of primary mice and 167 transplanted into secondary mice. YFP+ engrafted mice showed 3.9% (0.8-9.7%) median human 168 cell chimerism, while YFP-mice showed 30.4% (7.7-48.2%) ( Fig. 3e) . YFP expression in the 169 engrafted human cells was 0.27% (0-1.35) for YFP-cells, and 41.9% (20.8-100) for YFP+ cells 170 ( Fig. 3f) . Similar levels of human cell chimerism were observed for the SFFV-driven constructs 171 in serial transplants (Extended data Fig. 4) . Collectively, the presence of YFP expressing cells at 172 16-and 32-weeks post-modification demonstrates that cells with long-term repopulation potential 173 can be edited, albeit at lower frequencies than cells that did not undergo HR-GE. 174
To establish the modified cells' ability to differentiate into multiple hematopoietic lineages, we 175 looked in vitro using colony formation assays (CFAs) and in vivo after engraftment in NSG mice. 176
In CFAs, CB-derived and PB-derived YFP-expressing cells gave rise to all progenitor cells at the 177 same frequencies as mock treated and YFP-cells, indicating that IDUA-HSPCs can proliferate 178 and differentiate into multiple lineage progenitors in response to appropriate growth factors 179 (Extended data Fig. 5a, b) . In vivo, B, T and myeloid cells were identified using the human CD19, 180 CD3, and CD33 markers. Compared to mock cells that demonstrated a roughly equal distribution 181 of B and myeloid cells (1:1, CD19:CD33) 16 post-transplantation, YFP+ and YFP-cells showed 182 skewing towards myeloid differentiation (YFP+ = 1:16, and YFP-= 1:5) (Extended data Fig. 5c ). 183
Subgrouping the mice based on human-cell chimerism showed that in mice with low human 184 engraftment (< 1%), the cells exhibited myeloid skewing (72% of these mice had human myeloid 185 cell fractions >90%). In contrast, mice with chimerism greater than 20% displayed a mean CD33+ 186 fraction of 55% (Extended Data Fig. 5d, e ). This myeloid bias was not observed in circulating 187 cells in the peripheral blood or in secondary transplants (Extended data Fig. 5f, g) . These data 188 suggest that myeloid skewing is tightly and inversely correlated with the degree of human cell 189 engraftment, and that neither the genome editing process, nor IDUA expression, affects the 190 modified cell's capacity to differentiate into multiple hematopoietic lineages in vitro or in vivo. 191
192

Biochemical correction in NSG-IDUA X/X mice by human IDUA-HSPCs 193
To determine the potential of human IDUA-HSPCs to correct the metabolic abnormalities of 194 MPSI, we established a new mouse model of the disease capable of engrafting human cells. NSG-195 IDUA X/X mice replicated the phenotype of patients affected with MPSI 1 and previously described 196 immunocompetent 19, 20 and immunocompromised 21 
MPSI mice (Supplementary Data 3, 197
Extended data Fig. 6 and 7) . We focused the correction experiments on cells expressing IDUA 198 under the PGK promoter, as this promoter has better translational potential because it has 199 decreased enhancer-like activity compared to SFFV 22 . As a first series of experiments, we 200 examined PB-derived cells in which the modification did not include a selection marker. In bulk 201 10   To investigate the effect of IDUA-HSPCs on the skeletal and neurological manifestations of MPSI,  231 sham-treated and transplanted mice also underwent whole body micro-CT and neurobehavioral 232 studies 18 weeks after transplantation. The effect of transplantation on the skeletal system was 233 measured on the skull parietal and zygomatic bone thickness and the cortical thickness and length 234 of femoral bones. In experiments where the mice were transplanted using unselected cells and 235 where human cell chimerism was high ( Fig. 4d) , we observed almost complete normalization of 236 bone parameters by visual inspection and on CT scan measurements ( Fig. 5a, b) . Mice transplanted 237 with cells that had undergone selection showed partial but statistically significant reduction in the 238 thickness of the zygomatic, parietal bones, and femur ( Fig. 5c) . 239
We also examined the open field behavior, passive inhibitory avoidance, and marble-burying 240 behavior of sham-treated and transplanted mice. Transplantation of bulk-edited cells resulted in 241 marked reduction in locomotor activity and long-term memory, regardless of genotype (Extended 242 Data Fig. 9a-c) . We suspected that high human-cell chimerism was detrimental for the overall 243 health of the mice. Consistent with this, we observed growth restriction following human cell 244 transplantation in both homozygous and heterozygous mice (Extended Data Fig. 8a ). This likely 245 represents a toxicity artifact of this xenogeneic transplant model and could be explained in part by 246 the defective erythropoiesis seen in these xenograft models 23 when human cell chimerism is high. 247
In contrast, NSG-IDUA X/X mice transplanted with YFP-selected cells in which human cell 248 chimerism was low exhibited locomotor activity indistinguishable from their sham-treated 249 heterozygous littermates, and markedly higher that the sham-treated knock-out mice ( Fig. 5d) . 250 These mice also had increased vertical counts at all time points and demonstrated the same 251 exploratory behavior as sham heterozygous mice ( Fig. 5e ). Transplantation of IDUA-HSPCS in 252 NSG-IDUA X/X also enhanced performance in the passive inhibitory avoidance test 24 hours later 253 ( Fig. 5f ). Digging and marble burying behavior also improved but did not completely normalize 254 ( Fig. 5g) . 255 256
Safety of our genome editing strategy 257
To assess genotoxicity and characterize the off-target repertoire of our CCR5 guide, we used the 258 bioinformatics-based tool COSMID (CRISPR Off-target Sites with Mismatches, Insertions, and 259 Deletions) 24 . Off-target activity at a total of 67 predicted loci was measured by deep sequencing 260 in two biological replicates of CB-derived HSPCs. In each replicate we compared the percent 261 Indels measured in mock and cells electroporated with RNP with either wild-type (WT) Cas9 or a 262 higher fidelity (HiFi) Cas9 25 . Five of the 67 sites were located within repetitive elements and Indel 263 rates could not be assigned to specific loci in this group (Extended Data Fig. 10 ). For the 264 remaining 62 genomic locations, sites were deemed true off-targets if: 1) the percent of indels at 265 the site was > 0.1% (limit of detection), 2) off-target activity was present in both biological 266 samples, and 3) indels were higher in the RNP compared with the mock samples. Given these 267 criteria only 4 sites were deemed to be true off-targets (Figure 6a, b) . For all of these sites the 268 frequency of Indels was < 0.5% and the use of the HiFi Cas9 abolished off-target activity entirely 269 while maintaining on-target efficiency. Only one exonic site was found in the SUOX gene (sulfite 270 oxidase). The highest off-target activity measured at this site was 0.128%, which was reduced 271 below the limit of detection with HiFi Cas9. These data suggest that our CCR5 sgRNA combined 272 with either WT Cas9 or especially HiFi Cas9 has negligible off-target activity on a large screen of 273 bioinformatically predicted sites. 274
Collectively, we performed 191 autopsies (101 mice used in primary engraftment, 50 in secondary 275 engraftment, and 40 in NSG-IDUA X/X correction studies) in which no gross tumors were found. 276
Three tumor-like masses were evaluated by histology and confirmed to be abscesses. These 191 277 mice were transplanted with a combined dose of 90 million human cells that underwent our 278 genome editing protocol. Considering that the median age for HSCT in MSPI patients is around 279 one year 26 , and that an average one year-old is 10 Kg, the total number of modified cells used in 280 this study is roughly equivalent to two clinical doses of 4.5 x 10 6 CD34 HSPCs/kg. We conclude 281 that the apparent lack of tumorigenicity and the low off-target activity of the CCR5 sgRNA provide 282 evidence for the safety our modification strategy. 283 284 12
Discussion 285
We describe an efficient application of RNP and AAV6-mediated template delivery to overexpress 286 IDUA from a safe harbor locus in human CD34+ HSPCs. The suitability for CCR5 to be a safe 287 harbor for the insertion and expression of therapeutic genes has been described 22, 27 . For LSDs like 288 MPSI, the use of the safe harbor has several advantages compared to genetic correction of the 289 affected locus: 1) it enhances therapeutic potential, as it allows for supra-endogenous expression, 290
2) it circumvents design for specific mutations, 3) the coding sequences can be engineered with 291 enhanced therapeutic properties, e.g., crossing the blood brain barrier 28 , and 4) it is versatile and 292 easily adaptable to other LSDs. 293
Our approach attempts to commandeer the patient's own hematopoietic system to express and 294 deliver lysosomal enzymes. Because of the unique ability of this system to generate tissue 295 macrophages that can migrate into affected tissues to deliver the enzyme 29 , an HSCT-based 296 approach will likely be more effective that other potential enzyme depots 29 for harder-to-treat 297 organs like the CNS and bone. The autologous source for this approach also improves on safety, 298 by eliminating the morbidity of graft rejection, graft-versus-host disease, and immunosuppression, 299 and can lead to earlier intervention by obviating the need for donor matching. 300
We studied the self-renewal and multi-lineage differentiation capacity of the modified cells to 301 establish the potential of genome-edited HSPCs as one-time therapy for MPSI. Our data 302 demonstrates that this approach can modify cells with long-term repopulation potential and 303 preserves multi-lineage differentiation capacity in vivo and in vitro. In experiments comparing 304 engraftment potential of the YFP-and YFP+ cells, as well as in bulk transplantation experiments, 305 cells that underwent HR-GE had approximately a 5-fold lower long-term engraftment capacity. 306 This is not entirely surprising, as HR efficiencies are higher in cycling cells 30, 31 and therefore 307 would be expected to be lower in stem than progenitor cells. The lower engraftment could also 308 represent a negative effect of expression of a foreign fluorescent protein in HSCs 32 as previously 309 substituting a truncated form of the low-affinity nerve growth factor receptor resulted in higher 310 engraftment frequencies than using a fluorescent protein to mark HR-GE cells 15 . As observed in 311 allo-HSCT, this engraftment challenge might be circumvented by using larger doses of genome 312 edited cells. This can be achieved through selection followed by in vitro expansion in optimized 313 13 culturing conditions that could help maintain self-renewal capacity, perhaps including recently 314 discovered small molecules such as UM171 33 and SR1 34 . 315
Ex vivo manipulation of the HSPCs allows for a thorough examination of the genotoxicity and the 316 magnitude of biochemical potency of the cells before delivering the engineered cell drug product 317 to patients. Through a bioinformatics-guided strategy we identified four potential off-target sites 318 with minimal off-target activity. Fortunately, all were reversed by using a higher fidelity 319 nuclease 25 . The conclusion that our genome editing strategy is safe is also supported by the lack 320 of tumorigenicity in 191 mice transplanted with 90 million edited cells. 321
We examined the therapeutic potential of the edited HSPCs in a new model of MPSI capable of 322 robust human cell engraftment. Engraftment of the IDUA-HPSCs led to reconstitution of enzyme 323 activity and decreased GAG storage in multiple organs. Notably, small changes in circulating and 324 tissue IDUA lead to significant phenotypic improvements. This is not surprising as even a small 325 fraction of normal IDUA activity can dramatically improve the physical manifestations of MPSI. 326
Mean IDUA activity in fibroblasts from patients with severe MPSI is 0.18% (range 0-0.6), while 327 0.79% residual activity (range 0.3-1.8) results in mild disease (minimal neurological involvement 328 and the possibility of a normal life span) 35 . In fact, healthy individuals can be found with enzymatic 329 activity as low as 4% 36 . Our data constitutes the first study to show symptomatic correction of an 330 LSD with human genome-edited HSPCs and provides support for the further development of this 331 strategy for the treatment of the visceral, skeletal, and neurological manifestations in MPSI. 332
In sum, these pre-clinical studies provide proof-of-concept evidence of the safety and efficacy of 333 using genome-edited human HSPCs modified to express a lysosomal enzyme to correct the 334 biochemical, structural, and behavioral phenotype of a mouse model of MPSI, a canonical 335 lysosomal storage disease. Moreover, this work provides specific evidence of safety and efficacy 336 to support the optimization and development of this strategy into a clinical protocol to treat patients 337 with MPSI and a platform approach to potentially treat other lysosomal storage disorders. 338 CCR5 locus on CFA-derived colonies. This strategy did not distinguish WT versus alleles with 419 indels (NHEJ). b, Example agarose gels of 40 colonies genotyped in this manner. A single 1.1Kb 420 band was interpreted as WT/NHEJ in both alleles, while a single 0.6 Kb band was read as bi-allelic 421 integration. c, Schematic of probe design for ddPCR analysis. Fraction of modified alleles was 422 obtained by using a second reference probe to the CCRL2 gene also on chromosome 3p. d, 423
Originally two probes where each straddled a 5' or 3' homology arm were designed. The accuracy 424 of the assays was verified and compared using genomic DNA from colonies derived from mono-425 allelic cells (0.5 fraction of alleles modified). Error bars indicate 95% CI. The 3' HA probe was 426 selected. e, CCR5 allele targeting frequencies in CB (red) and PB (blue)-derived IDUA expressing 427 HSPCs as measured by ddPCR. The mean fraction of modified alleles in CB-HSPCs for the SFFV 428 and PGK-driven donors was 23% ± 6, 21% ± 8 respectively, and 41% ± 5 for the cassette lacking 429
YFP. 430
Extended Data Fig. 3 | a Table  490 lists all 67 COSMID predicted sites, the sequence, genomic location, percent Indels in two 491 experiments and the number of reads for each site and in each experiment. Samples with percent 492 Indels > 0.1% are highlighted in pink. Samples with low coverage are highlighted in light yellow. 493 CCR5 _OT63 through 67 were located within a repetitive element. Three of these had primers that 494 should have been unique per locus but the Indel analysis showed that this was not the case. 495 Therefore, the true off-target rate at these sites were not ascertainable but should all be < 0.5%. 496
Methods 497 498 AAV donor plasmid construction 499
The CCR5 donor vectors have been constructed by PCR amplification of ~ 500 bp left and right 500 homology arms for the CCR5 locus from human genomic DNA. SFFV, PGK, IDUA sequences 501 were amplified from plasmids. Primers were designed using an online assembly tool (NEBuilder, 502 New England Biolabs, Ipswich, MA, USA) and were ordered from Integrated DNA Technologies 503 (IDT, San Jose, CA, USA). Fragments were Gibson-assembled into a the pAAV-MCS plasmid 504 (Agilent Technologies, Santa Clara, CA, USA). 505 506 rAAV production 507
We followed a protocol that has been previously reported with slight modifications 1 Technologies. For DNA extraction from 96-well plates, PBS was added to wells with colonies, 588 and the contents were mixed and transferred to a U-bottomed 96-well plate. Cells were pelleted by centrifugation at 300xg for 5 min followed by a wash with PBS. Finally, cells were resuspended 590 in 25 µl QuickExtract DNA Extraction Solution (Epicentre, Madison, WI, USA) and transferred 591 to PCR plates, which were incubated at 65°C for 10 min followed by 100°C for 2 min. For CCR5, 592 
NSG-IDUA X/X mice 724
We used CRISPR/Cas9 to knock-in the W401X mutation (UniProtKB -Q8BMG0), analogous to 725 the W402X mutation commonly found in patients with severe MPSI, into NSG mouse embryos 7 . 726
The guide RNA target sequence was searched using crispr.mit.edu and six shortlisted guides 727 close to the target site were first screened by using an in vivo assay in NIH 3T3 cells. Two 728 guides, one each on both sides of the target site, were selected: Guide1 were performed using standard protocols described previously 8 . A total of 38 zygotes were 751 injected, the surviving 27 zygotes were transferred, which yielded 7 live offspring. Among these 752 a male homozygous for the mutation was used to establish the NSG-IDUA X/X colony. Mice were 753 genotyped by-PCR based amplification followed by Sanger sequencing using the following We thank Stanford's behavioral and functional neurosciences laboratory for advice with 766 neurobehavioral studies. We also thank Stanford's Binns Program for Cord Blood Research for 767 providing cells. We also would like to give thanks to the members of the Porteus laboratory for 768 input, comments, and discussion. Table summarizing four bona fide off-target sites. PAM sequences are shown in red and mismatched bases are shown in blue. For all of these sites the percent of Indels was < 0.5%. For all of these sites, the use of the HiFi Cas9 abolished off-target activity. CCR5  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61 Fig. 2 | Efficiency of modification at the CCR5 locus. a, Schematic showing the three primer-based genotyping scheme to distinguish mono and bi-allelic integration into the CCR5 locus on CFA-derived colonies. This strategy did not distinguish WT versus alleles with indels (NHEJ). b, Example agarose gels of 40 colonies genotyped in this manner. A single 1.1Kb band was interpreted as WT/NHEJ in both alleles, while a single 0.6 Kb band was read as bi-allelic integration. c, Schematic of probe design for ddPCR analysis. Fraction of modified alleles was obtained by using a second reference probe to the CCRL2 gene also on chromosome 3p. d, Originally two probes where each straddled the 5' or 3' homology arm were designed. The accuracy of the assays was verified and compared using genomic DNA from colonies derived from mono-allelic cells (0.5 fraction of alleles modified). Error bars indicate 95% CI. The 3' HA probe was selected. e, CCR5 allele targeting frequencies in CB (red) and PB (blue)-derived IDUA expressing HSPCs as measured by ddPCR. No comparison was found to be significant. b, Total ambulatory distance in 10 minutes. c, Memory for inhibitory avoidance training (24h). No comparison was found to be significant. Comparisons between groups were performed using one-way ANOVA test and post-hoc comparisons were made with the Tukey's multiple comparisons test. Open field testing and vertical rearings were analyzed using within-subject modeling by calculating the are under the curve for each mouse for the entire time course and comparing between groups with one-way ANOVA.
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